Clinical Trials
136 trialsNCT06643715 2026-06-05
Research of the Application of Pancreatic Cancer Screening Artificial Intelligence Model "PANDAPro"
Zhejiang University
Phase NA Active not recruiting
NCT04753879 2026-06-03
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT02451982 2026-06-01
Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT03257761 2026-06-01
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
University of Southern California
Phase 1 Active not recruiting
NCT03935893 2026-06-01
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
University of Pittsburgh
Phase 2 Active not recruiting
NCT04594772 2026-06-01
Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma
University of Cincinnati
Phase 2 Active not recruiting
NCT06090916 2026-05-26
Malnutrition Screening and Dietary Intervention to Improve Nutrition Outcomes in Patients With Unresectable Pancreatic Cancer
Jonsson Comprehensive Cancer Center
Phase NA Active not recruiting
NCT04452357 2026-05-22
Pulse-low-dose Rate (PLDR) Radiation in Pancreatic Cancer
Fox Chase Cancer Center
Phase NA Active not recruiting
NCT04484909 2026-05-22
NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT03187951 2026-05-20
PancFit: Multimodal Exercise During Preoperative Therapy for Pancreatic Cancer
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT07173387 2026-05-19
RAD-NALIRIFOX
Shandong Cancer Hospital and Institute
Phase 2 Active not recruiting
NCT04137536 2026-05-15
A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT04927780 2026-05-15
PREOPANC-3
Erasmus Medical Center
Phase 3 Active not recruiting
NCT01972919 2026-05-12
MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer
Medical College of Wisconsin
Phase 2 Active not recruiting
NCT04106856 2026-05-12
SHAPER
University of Utah
Phase 1 Active not recruiting
NCT04331041 2026-05-08
Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
Washington University School of Medicine
Phase 2 Active not recruiting
NCT03523312 2026-05-06
MAIBE
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05220046 2026-05-06
Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers
University of Nebraska
Phase 1 Active not recruiting
NCT06015659 2026-05-04
ZN-c3 + Gemcitabine in Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT05043857 2026-04-30
SPARTA
Istituto Clinico Humanitas
Phase NA Active not recruiting
NCT02495896 2026-04-29
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
University of Southern California
Phase 1 Active not recruiting
NCT04887805 2026-04-29
Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT03631173 2026-04-28
MINIMUM
Oslo University Hospital
Phase NA Active not recruiting
NCT03033927 2026-04-27
Predicting Effective Therapy in Pancreatic Cancer
Memorial Sloan Kettering Cancer Center
Active not recruiting
NCT04837833 2026-04-27
An Ultrasound Imaging Technique to Measure Tumors in People With Pancreatic Ductal Adenocarcinoma (PDAC) or Gastrointestinal (GI) Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase NA Active not recruiting
NCT03682289 2026-04-23
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
Phase 2 Active not recruiting
NCT04544046 2026-04-21
Supportive Oncology Care At Home RCT
Massachusetts General Hospital
Phase NA Active not recruiting
NCT05632328 2026-04-20
AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC
Beth Israel Deaconess Medical Center
Phase 2 Active not recruiting
NCT04940286 2026-04-16
Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05497778 2026-04-16
A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT03168737 2026-04-15
18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04837118 2026-04-15
Resistance Training Intervention to Improve Physical Function in Patients With Pancreatic Cancer Receiving Combination Chemotherapy or Have Undergone Surgery, PancStrength Study
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT05692323 2026-04-15
PREHAB
Cedars-Sinai Medical Center
Phase NA Active not recruiting
NCT04449406 2026-04-07
UroPanc
Queen Mary University of London
Active not recruiting
NCT04820179 2026-04-02
Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer
University of Arizona
Phase 2 Active not recruiting
NCT01580241 2026-04-01
Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer
University of Oklahoma
Active not recruiting
NCT06050395 2026-03-31
The MONITOR Study: Remote Monitoring Of a Nutrition Intervention To Optimize Treatment Response
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Active not recruiting
NCT03060720 2026-03-30
Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy
Dana-Farber Cancer Institute
Active not recruiting
NCT05984602 2026-03-30
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
NYU Langone Health
Phase 1 Active not recruiting
NCT04281290 2026-03-27
PanECT
University Medical Centre Ljubljana
Phase NA Active not recruiting
NCT04905082 2026-03-24
HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics
City of Hope Medical Center
Phase NA Active not recruiting
NCT04862260 2026-03-19
Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma
CHU de Quebec-Universite Laval
Phase EARLY_PHASE1 Active not recruiting
NCT06712797 2026-03-13
PANTHER-PIC
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Active not recruiting
NCT07457541 2026-03-12
Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI
Tomsk National Research Medical Center of the Russian Academy of Sciences
Phase 1 Active not recruiting
NCT03875820 2026-03-10
FRAME
Institute of Cancer Research, United Kingdom
Phase 1 Active not recruiting
NCT05677048 2026-03-09
Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT05836870 2026-03-02
Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 3 Active not recruiting
NCT07443761 2026-03-02
PANREG
University Hospital, Antwerp
Active not recruiting
NCT03164486 2026-02-27
First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide
University of California, Davis
Phase EARLY_PHASE1 Active not recruiting
NCT05642962 2026-02-25
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting